A substantial body of evidence has demonstrated the effectiveness of intensive low‐density lipoprotein cholesterol (LDL‐C) lowering therapy with statins and proprotein convertase subtilisin‐kexin type 9 (PCSK‐9) inhibitors, and the concept of ‘the lower, the better’ has been well established for both primary and secondary prevention in ASCVD [2, 3, 4]. This evidence concerns the gene PCSK9 and atherosclerosis.